Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation

IF 2.8 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Therapeutics Pub Date : 2026-01-15 DOI:10.1155/cdr/8733628

Bo Zheng, Meiling Li, Peng Wang, Jialong Lin, Haifeng Pei, Hao Liu, Xianglin Ye

{"title":"Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation","authors":"Bo Zheng, Meiling Li, Peng Wang, Jialong Lin, Haifeng Pei, Hao Liu, Xianglin Ye","doi":"10.1155/cdr/8733628","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The objectives of this study is to investigate the correlation between genotype polymorphism of aldehyde dehydrogenase 2 (ALDH2) and coronary artery disease (CAD) in atrial fibrillation patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>From November 2020 to December 2021, 80 patients with atrial fibrillation at a medical center in Chengdu were divided into two groups: CAD group (<i>n</i> = 25) and non-CAD group (<i>n</i> = 55). The genotype composition ratio of ALDH2 (mutant-type/wild-type), blood biochemical indexes, the proportion of the history of lipid-lowering drugs and time of taking lipid-lowering drug were compared between the two groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The CAD group showed significantly lower levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) compared with the non-CAD group (<i>p</i> < 0.05), and the proportion and time of taking lipid-lowering drugs in CAD group were significantly increased (<i>p</i> < 0.05). The frequency of the ALDH2 genotype (mutant-type/wild-type) in the CAD group was notably elevated compared with that in the non-CAD group (<i>p</i> < 0.05). In patients with atrial fibrillation, the risk of CAD in patients with ALDH2 mutant genotype (GA + AA) was 5.849 times that of ALDH2 wild-type genotype (GG) (95<i>%</i>CI = 1.437–23.795, <i>p</i> < 0.05). The area under ROC curve of ALDH2 mutant genotype (GA + AA) was 0.624 (SE = 0.069, 95<i>%</i>CI : 0.488–0.759). In patients with ALDH2 wild-type (GG), the levels of total cholesterol and LDL-C in CAD group were significantly lower than those in non-CAD group (<i>p</i> < 0.05). However, in patients with ALDH2 mutation genotype (GA + AA), the proportion of history of lipid-lowering drugs in CAD group was significantly higher than that in non-CAD group (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The polymorphism of ALDH2 gene is a high risk factor for CAD in patients with atrial fibrillation. The ALDH2 mutation genotype (GA + AA) may reduce the lipid-lowering efficacy of statins.</p>\n </section>\n </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808927/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/8733628","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

The objectives of this study is to investigate the correlation between genotype polymorphism of aldehyde dehydrogenase 2 (ALDH2) and coronary artery disease (CAD) in atrial fibrillation patients.

Methods

From November 2020 to December 2021, 80 patients with atrial fibrillation at a medical center in Chengdu were divided into two groups: CAD group (n = 25) and non-CAD group (n = 55). The genotype composition ratio of ALDH2 (mutant-type/wild-type), blood biochemical indexes, the proportion of the history of lipid-lowering drugs and time of taking lipid-lowering drug were compared between the two groups.

Results

The CAD group showed significantly lower levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) compared with the non-CAD group (p < 0.05), and the proportion and time of taking lipid-lowering drugs in CAD group were significantly increased (p < 0.05). The frequency of the ALDH2 genotype (mutant-type/wild-type) in the CAD group was notably elevated compared with that in the non-CAD group (p < 0.05). In patients with atrial fibrillation, the risk of CAD in patients with ALDH2 mutant genotype (GA + AA) was 5.849 times that of ALDH2 wild-type genotype (GG) (95%CI = 1.437–23.795, p < 0.05). The area under ROC curve of ALDH2 mutant genotype (GA + AA) was 0.624 (SE = 0.069, 95%CI : 0.488–0.759). In patients with ALDH2 wild-type (GG), the levels of total cholesterol and LDL-C in CAD group were significantly lower than those in non-CAD group (p < 0.05). However, in patients with ALDH2 mutation genotype (GA + AA), the proportion of history of lipid-lowering drugs in CAD group was significantly higher than that in non-CAD group (p < 0.05).

Conclusions

The polymorphism of ALDH2 gene is a high risk factor for CAD in patients with atrial fibrillation. The ALDH2 mutation genotype (GA + AA) may reduce the lipid-lowering efficacy of statins.

Abstract Image

查看原文本刊更多论文

ALDH2基因多态性与房颤患者冠状动脉疾病的相关性

目的：探讨房颤患者醛脱氢酶2 （ALDH2）基因型多态性与冠心病（CAD）的相关性。方法：于2020年11月至2021年12月，将成都市某医疗中心收治的80例房颤患者分为CAD组（n = 25）和非CAD组（n = 55）。比较两组患者ALDH2基因型组成比（突变型/野生型）、血液生化指标、使用降脂药物的比例及服用降脂药物的时间。结果：冠心病组总胆固醇、低密度脂蛋白胆固醇（LDL-C）水平明显低于非冠心病组（p < 0.05），冠心病组服用降脂药物的比例和时间明显增加（p < 0.05）。与非CAD组相比，CAD组ALDH2基因型（突变型/野生型）频率显著升高（p < 0.05）。在房颤患者中，ALDH2突变基因型（GA + AA）患者发生CAD的风险是ALDH2野生基因型（GG）患者的5.849倍（95%CI = 1.437 ~ 23.795, p < 0.05）。ALDH2突变基因型（GA + AA）的ROC曲线下面积为0.624 （SE = 0.069, 95%CI: 0.488 ~ 0.759）。在ALDH2野生型（GG）患者中，CAD组总胆固醇和LDL-C水平显著低于非CAD组（p < 0.05）。而在ALDH2突变基因型（GA + AA）患者中，CAD组使用降脂药物的比例显著高于非CAD组（p < 0.05）。结论：ALDH2基因多态性是心房颤动患者冠心病的高危因素。ALDH2突变基因型（GA + AA）可能会降低他汀类药物的降脂效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Therapeutics 医学-心血管系统

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.